ALLO

NASDAQ 已收盘

Allogene Therapeutics

0.67 USD
▼-0.03-4.17%
盘后 0.67 +0.91%
2026-11-19
市值
$217.48M
市盈率
—
EPS
-0.61
股息率
—
52 周区间
0.65 – 4.46
成交量
7.41M
Beta
0.78
目标价
9.00
52W 低 0.6552W 高 4.46
价格走势

公司简介

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ...